AstraZeneca drug approved in US to reduce risk of heart failure in type-2 diabetes patients

Writer, Stock Market Wire
Monday, October 21, 2019 - 07:31

AstraZeneca said its type-2 diabetes drug was approved by US regulators to reduce the risk of hospitalisation for heart failure in adults with type-2 diabetes and established cardiovascular disease.

The approval comes on the back of results from the Declare-Timi 58 cardiovascular outcomes trial (CVOT), to evaluate type-2 diabetes (T2D) patients with multiple CV risk factors or established CV disease.

'This is promising news for the 30 million people living with type-2 diabetes in the US, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke. Farxiga now offers the opportunity for physicians to act sooner and reduce the risk of hospitalisation for heart failure,' said Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit.

Related content

AstraZeneca diabetes drug approved by European Commission

AstraZeneca said its drug to improve glucose levels in adults with type-2 diabetes had been approved by the European Commission.

The approval was based...

Fri, 15/11/2019 - 07:42

AztraZeneca, MSD neurofibromatosis drug application accepted, granted priority review in US

AstraZeneca and MSD said their application for a drug used to treat paediatric patients suffering from neurofibromatosis had been accepted by the US Food and...

Thu, 14/11/2019 - 07:36

Four stocks priced for perfection and likely to disappoint investors


Controversial Brexiteer hedge fund manager Crispin Odey is fond of saying that cycles never die, or what goes up inevitably comes back down. What this...

Thu, 14/11/2019 - 00:00

AstraZeneca announces positive results for lupus drug from clinical trial

AstraZeneca said its lupus drug had shown superior results compared with a placebo in a clinical trial.

On the primary endpoint, lupus drug, anifrolumab, achieved...

Tue, 12/11/2019 - 07:35

AstraZeneca's drug to treat anaemia in kidney disease patients meets primary goal

AstraZeneca said pooled analyses had shown that its drug used to treat patients with anaemia from chronic kidney disease had met its primary goal with...

Mon, 11/11/2019 - 07:30